PHAXIAM Therapeutics S.A. (PHXM)
PHAXIAM Therapeutics S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lyon, FR. The stock last traded at $3.10, down 5.20% on the session, giving a market capitalisation of $19.9M. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of -1771.3%. Its beta of 1.80 implies it has historically moved more than the broad market.
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, which is currently undergoing Phase 3 clinical trials for advanced pancreatic cancer (second-line treatment) and Phase 2 studies for triple-negative breast cancer and relapsed acute lymphoblastic leukemia. Additionally, PHAXIAM is advancing a range of phage-based therapies designed to combat severe, drug-resistant bacteria. These pathogens are responsible for over two-thirds of nosocomial (hospital-acquired) infections that resist conventional treatments, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Established in 2004 and headquartered in Lyon, France, the company was previously known as ERYTECH Pharma S.A. before adopting its current name, PHAXIAM Therapeutics S.A., in June 2023.
PHAXIAM Therapeutics S.A. is most often compared with the following Healthcare names: